Richard S. Lindahl - 07 May 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Chief Financial Officer
Signature
/s/ Richard S. Lindahl
Issuer symbol
EBS
Transactions as of
07 May 2025
Net transactions value
$0
Form type
4
Filing time
06 Mar 2026, 08:50:53 UTC
Previous filing
10 Mar 2025
Next filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LINDAHL RICHARD S EVP, Chief Financial Officer 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl 06 Mar 2026 0001196632

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Option (Right to buy) Expiration (or cancellation) of long derivative position with value received -19,963 -100% $0.000000* 0 07 May 2025 Common Stock 19,963 $48.33 Direct F1, F2
transaction EBS Employee Stock Option (Right to buy) Expiration (or cancellation) of long derivative position with value received -20,321 -100% $0.000000* 0 25 Feb 2026 Common Stock 20,321 $61.01 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported stock options expired unexercised pursuant to their terms and no value was received.
F2 Vested in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021.
F3 Vested in three equal installments beginning on the day prior to the first anniversary of the date of grant, subject to continued service with the company.

Remarks:

This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in its next proxy statement.